Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 207

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The JAK2V617Ftyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

Open access
Tefferi, Ayalew, Lasho, Terra L., Schwager, Susan M., Steensma, David P., Mesa, Ruben A., Li, Chin‐Yang, Wadleigh, Martha, Gary Gilliland, D. · 2005 · British Journal of Haematology

Abstract

Summary: An association between an activating JAK2 mutation (JAK2V617F) and BCR/ABL‐negative myeloproliferative disorders was recently reported in multiple simultaneous publications. In the current study, mutation analysis for JAK2V617F was performed in peripheral blood mononuclear cells (PBMC) from 157 patients with myelofibrosis with myeloid metaplasia (MMM) including 117 with agnogenic (AMM), 22 with postpolycythaemic (PPMM), and 18 with post‐thrombocythaemic (PTMM) myeloid metaplasia. The detection rate for JAK2V617F was significantly higher in PPMM (91%; homozygous in 18%) compared with either AMM (45·3%; homozygous in 2·6%) or PTMM (38·9%; homozygous in 11·1%). Concomitant analysis in granulocytes (n = 57) and CD34+cells (n = 25) disclosed a higher incidence of homozygous JAK2V617F mutation but the overall mutation rate was similar to that obtained from PBMC.JAK2V617F was not detected in DNA derived from T cells (n = 19). In AMM, the presence of JAK2V617F was associated with an older age at diagnosis and a history of thrombosis or pruritus. Multivariate analysis identified only age and the Dupriez prognostic score as independent prognostic factors;JAK2V617F had no prognostic significance. In conclusion,JAK2V617F is a myeloid lineage‐specific event, its incidence in MMM is significantly higher with an antecedent history of polycythaemia vera (PV), and its presence in AMM does not affect prognosis but is associated with PV‐characteristic clinical features.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2005.05776.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 207

Metadata

Authors
Tefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A., Li, C., Wadleigh, M., & Gary Gilliland, D.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2005-10-17
Volume
131
Issue
3
Pages
320-328
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2022159066
Cited by
207
References
1
FWCI
13.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The JAK2V617Ftyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. https://app.cochat.ai/papers/10.1111/j.1365-2141.2005.05776.x
The paper
Tefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A., Li, C., Wadleigh, M., & Gary Gilliland, D. (2005). The JAK2V617Ftyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2005.05776.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.